for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

Spectrum Pharmaceuticals, Inc.

SPPI.O

Latest Trade

1.96USD

Change

-0.09(-4.39%)

Volume

2,065,635

Today's Range

1.95

 - 

2.06

52 Week Range

1.92

 - 

5.24

As of on the NASDAQ ∙ Minimum 15 minute delay

Pricing

Previous Close
2.05
Open
2.03
Volume
2,065,635
3M AVG Volume
55.87
Today's High
2.06
Today's Low
1.95
52 Week High
5.24
52 Week Low
1.92
Shares Out (MIL)
164.07
Market Cap (MIL)
336.35
Forward P/E
-1.80
Dividend (Yield %)
--

Next Event

Q3 2021 Spectrum Pharmaceuticals Inc Earnings Release

Latest Developments

More

Spectrum Pharma Reports Q2 NON-GAAP Loss Per Share Of $0.25

Spectrum Pharmaceuticals Receives Complete Response Letter From FDA For ROLONTIS

Spectrum Pharmaceuticals Inc Files For Mixed Shelf Of Upto $300 Mln- SEC Filing

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up

About Spectrum Pharmaceuticals, Inc.

Spectrum Pharmaceuticals, Inc. is a biopharmaceutical company. The Company's product portfolio consists of in-development drug products for the treatment of cancer patients. Its pipeline products include ROLONTIS, Poziotinib and Anti-CD20-IFNa. ROLONTIS (eflapegrastim injection), is a long-acting granulocyte colony-stimulating factor (G-CSF) for chemotherapy-induced neutropenia. Poziotinib, is a pan-HER inhibitor that irreversibly blocks signaling through the Epidermal Growth Factor Receptor (EGFR) family of tyrosine-kinase receptors, including HER1 (erbB1; EGFR), HER2 (erbB2), HER4 (erbB4), and HER receptor mutations. Anti-CD20-IFNa, is an antibody-interferon fusion molecule directed against CD20 that is in Phase I development for treating relapsed or refractory non-Hodgkin's lymphoma (NHL) patients.

Industry

Biotechnology & Drugs

Contact Info

11500 S Eastern Ave Ste 240

HENDERSON, NV

89052-5576

United States

+1.702.8356300

https://www.sppirx.com/

Executive Leadership

William L. Ashton

Independent Chairman of the Board

Joseph W. Turgeon

President, Chief Executive Officer, Director

Kurt A. Gustafson

Chief Financial Officer, Executive Vice President

Thomas J. Riga

Chief Operating Officer, Chief Commercial Officer, Executive Vice President

Francois J. Lebel

Executive Vice President, Chief Medical Officer

Key Stats

2.17 mean rating - 6 analysts
Sell
Hold
Buy
Revenue (MM, USD)

2018

0.1K

2019

0.0K

2020

0.0K

2021(E)

0.0K
EPS (USD)

2018

-0.840

2019

-1.020

2020

-1.290

2021(E)

-1.113
Price To Earnings (TTM)
--
Price To Sales (TTM)
--
Price To Book (MRQ)
3.10
Price To Cash Flow (TTM)
--
Total Debt To Equity (MRQ)
0.00
LT Debt To Equity (MRQ)
0.00
Return on Investment (TTM)
-143.20
Return on Equity (TTM)
-99.67

Latest News

Latest News

FDA delays decision on Spectrum Pharma's drug candidate due to travel curbs

The U.S. health regulator has deferred a decision on Spectrum Pharmaceuticals' <SPPI.O> drug candidate to treat chemotherapy induced loss of white blood cells in cancer patients due to COVID-19 related travel curbs, the company said on Monday.

FDA delays approval of Spectrum Pharma's drug due to COVID-19

Spectrum Pharmaceuticals said on Monday the U.S. Food and Drug Administration has deferred approval of its experimental drug for treating chemotherapy induced loss of white blood cells in cancer patients, due to COVID-19 related travel restrictions.

BRIEF-Spectrum To Present Preclinical Rolontis Same Day Dosing Data

* SPECTRUM PHARMACEUTICALS TO PRESENT PRECLINICAL ROLONTIS® (EFLAPEGRASTIM) SAME DAY DOSING DATA AT AACR VIRTUAL ANNUAL MEETING II Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharmaceuticals Reports Q1 Loss Per Share Of $0.36

* SPECTRUM PHARMACEUTICALS REPORTS FIRST QUARTER 2020 FINANCIAL RESULTS AND PIPELINE UPDATE

BRIEF-Spectrum Pharmaceuticals Initiates Same Day Dosing Clinical Trial For Rolontis

* SPECTRUM PHARMACEUTICALS INITIATES SAME DAY DOSING CLINICAL TRIAL FOR ROLONTIS® (EFLAPEGRASTIM) Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharmaceuticals Provides Strategy Update For Poziotinib Development Program

* SPECTRUM PHARMACEUTICALS PROVIDES STRATEGY UPDATE FOR POZIOTINIB DEVELOPMENT PROGRAM

BRIEF-Spectrum Pharmaceuticals Files For Mixed Shelf Of Up To $150 Million - SEC Filing

* SPECTRUM PHARMACEUTICALS INC FILES FOR MIXED SHELF OF UP TO $150 MILLION - SEC FILING Source : (https://bit.ly/39dOjO0) Further company coverage:

BRIEF-Spectrum Pharma To Present Data From Phase 2 Clinical Trial For Poziotinib

* SPECTRUM PHARMACEUTICALS TO PRESENT DATA FROM PHASE 2 CLINICAL TRIAL FOR POZIOTINIB AT UPCOMING MEDICAL CONFERENCE Source text for Eikon: Further company coverage:

BRIEF-Spectrum Pharmaceuticals Posts Q4 Loss Per Share Of $0.36

* SPECTRUM PHARMACEUTICALS REPORTS FOURTH QUARTER 2019 AND FULL YEAR 2019 FINANCIAL RESULTS AND PIPELINE UPDATE

Quote and financial data from Refinitiv. Fund performance data provided by Lipper. All quotes delayed a minimum of 15 minutes.

for-phone-onlyfor-tablet-portrait-upfor-tablet-landscape-upfor-desktop-upfor-wide-desktop-up